| Value | ₹2,150 Cr |
|---|
NSE filing, NSE: APLLTD. Summary written from the filing by ALFA Finder's alert engine.
Alembic Pharmaceuticals Ltd: key numbers
- Share price
- ₹836.20
- Market cap
- ₹16,437 Cr
- Revenue (annual)
- ₹7,345 Cr
- Net profit (annual)
- ₹674.8 Cr
- P/E (TTM)
- 23.7×Sector 41.3×
- Promoter holding
- 69.87%+0.00% QoQ
- FII holding
- 4.55%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Alembic Pharmaceuticals Ltd
All →Alembic Pharmaceuticals Other Announcement
Alembic Pharmaceuticals Limited has updated its list of Key Managerial Personnel authorised to determine materiality and make stock exchange disclosures. This update follows a board meeting held on November 4, 2026.
Alembic Pharmaceuticals Partnership
Alembic Pharmaceuticals expanded its strategic collaboration with DifGen Pharmaceuticals to commercialize over 20 complex generic products in the US. The portfolio targets a US$5 billion market.
- From
- DifGen Pharmaceuticals
- Execution
- Initial launches from FY28
Alembic Pharmaceuticals Investor Presentation: Key Takeaways
Q2 FY27 revenue ₹26.03bn (+36% YoY), PAT ₹3.35bn (+81%), EBITDA margin 22% (+520bps). US formulations led growth (+77%).
Alembic Pharmaceuticals Results Update
Alembic Pharmaceuticals reported Q2 FY27 revenue growth of 36% to ₹2,603 Crore. Net profit surged 81% to ₹335 Crore, driven by exceptional US business performance.
- Value
- ₹2,603 Cr
Alembic Pharmaceuticals Q2 FY27 Results: Net Profit ₹335.2 Cr, Up 81.5% YoY
Alembic Pharmaceuticals Ltd reported revenue from operations of ₹2,604 Cr (+36.3% YoY) and net profit of ₹335.2 Cr (+81.5% YoY) for Q2 FY27.
- Key figure
- Net profit ₹335.2 Cr · +81.5% YoY
Alembic Pharmaceuticals Board Meeting Date
Alembic Pharmaceuticals scheduled its board meeting for November 4, 2026, to consider unaudited Q1/H1 FY27 results. Trading window re-opens 48 hours post-declaration.
Other results update announcements
All →Vidya Wires Results Update
Vidya Wires Limited reported Q2 FY27 net profit of Rs.148.46 million and net sales of Rs.5,783.04 million. Unaudited consolidated figures cover the September 2026 quarter.
Cospower Engineering Results Update
Cospower Engineering reported H1 FY26-27 standalone PAT of ₹5.91 Crore, up 161.75%. Total revenue rose 87.22% to ₹60.94 Crore for the unaudited half year.
Orkla India Results Update
Orkla India's Q2 FY27 revenue rose 19.4% to ₹776 Crore and PAT rose 19.2% to ₹91 Crore. Figures are from the unaudited consolidated press release.
Aptus Value Housing Finance India Results Update
Aptus Housing Finance reported Q2 FY27 net profit of ₹267 Cr (up 18% YoY) and H1 net profit of ₹528 Cr, with AUM at ₹14,177 Cr. The investor press release also reiterated FY27 AUM growth guidance of around 22%.
Torrent Power Results Update
Torrent Power reported Q2 FY27 revenue of ₹9,801 Crore, up 24%, and EBITDA of ₹1,988 Crore, up 26%. Growth came from distribution, renewables and Nabha consolidation.
Ircon International Results Update
IRCON reported Q2 FY27 consolidated PAT of Rs.100.3 crore, down 26.5% YoY, with revenue up 14.9%. Order book stood at Rs.21,296 crore as on 30.09.2026.
- Order book
- ₹21,296 Cr